PhaseBio Pharmaceuticals Inc

2019 Q2 Form 10-Q Financial Statement

#000156459019031993 Filed on August 14, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2018 Q2

Balance Sheet

Concept 2019 Q2 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $90.30M $8.700M
YoY Change 937.93%
Cash & Equivalents $90.34M $8.734M
Short-Term Investments
Other Short-Term Assets $3.400M $200.0K
YoY Change 1600.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables $1.180M
Total Short-Term Assets $94.90M $9.000M
YoY Change 954.41%
LONG-TERM ASSETS
Property, Plant & Equipment $677.0K $300.0K
YoY Change 125.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $32.00K $700.0K
YoY Change -95.43%
Total Long-Term Assets $2.541M $900.0K
YoY Change 182.33%
TOTAL ASSETS
Total Short-Term Assets $94.90M $9.000M
Total Long-Term Assets $2.541M $900.0K
Total Assets $97.44M $9.900M
YoY Change 884.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.047M $600.0K
YoY Change 407.83%
Accrued Expenses $1.400M $2.400M
YoY Change -41.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $14.10M
YoY Change -100.0%
Long-Term Debt Due $1.265M $2.900M
YoY Change -56.38%
Total Short-Term Liabilities $5.746M $23.30M
YoY Change -75.34%
LONG-TERM LIABILITIES
Long-Term Debt $8.429M $5.300M
YoY Change 59.04%
Other Long-Term Liabilities $56.00K $0.00
YoY Change
Total Long-Term Liabilities $8.485M $5.300M
YoY Change 60.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.746M $23.30M
Total Long-Term Liabilities $8.485M $5.300M
Total Liabilities $15.83M $28.60M
YoY Change -44.65%
SHAREHOLDERS EQUITY
Retained Earnings -$139.4M
YoY Change
Common Stock $29.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $24.00K
YoY Change
Treasury Stock Shares $29.97K
Shareholders Equity $81.61M -$108.4M
YoY Change
Total Liabilities & Shareholders Equity $97.44M $9.900M
YoY Change 884.22%

Cashflow Statement

Concept 2019 Q2 2018 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address Address Line1
EntityAddressAddressLine1
1 Great Valley Parkway
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 30
dei Entity Address City Or Town
EntityAddressCityOrTown
Malvern
dei Entity Address State Or Province
EntityAddressStateOrProvince
Pennsylvania
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19355
dei City Area Code
CityAreaCode
610
dei Local Phone Number
LocalPhoneNumber
981-6500
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
90342000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61031000
CY2018Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
20000
CY2019Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1180000
CY2018Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
233000
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3375000
dei Entity File Number
EntityFileNumber
001-38697
dei Entity Shell Company
EntityShellCompany
false
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
030375697
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1344000
CY2019Q2 us-gaap Assets Current
AssetsCurrent
94897000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
43000
CY2019Q2 us-gaap Assets
Assets
97438000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
62628000
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
677000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4720000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
355000
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1832000
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
32000
CY2018Q4 us-gaap Assets
Assets
63026000
CY2019Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
56000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-139436000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-122911000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
22000
CY2019Q2 us-gaap Liabilities
Liabilities
15829000
CY2018Q4 us-gaap Liabilities
Liabilities
12099000
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
81609000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
1265000
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3047000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1806000
CY2019Q2 phas Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1434000
CY2018Q4 phas Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
2771000
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
5746000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4577000
CY2019Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8429000
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7500000
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1598000
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
29000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
25000
CY2019Q2 us-gaap Treasury Stock Value
TreasuryStockValue
24000
CY2018Q4 us-gaap Treasury Stock Value
TreasuryStockValue
24000
CY2019Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
221040000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
173837000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
50927000
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
97438000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
63026000
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28727607
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24528242
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28697640
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24498275
CY2019Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
29967
CY2018Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
29967
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1356000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7781000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5425000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1560000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
917000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
10185000
us-gaap Share Based Compensation
ShareBasedCompensation
508000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-22000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
250000
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2567000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
4107000
us-gaap Operating Expenses
OperatingExpenses
18222000
us-gaap Operating Expenses
OperatingExpenses
6985000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9482000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4107000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16866000
us-gaap Operating Income Loss
OperatingIncomeLoss
-6985000
CY2019Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
491000
CY2018Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
36000
us-gaap Investment Income Interest
InvestmentIncomeInterest
808000
us-gaap Investment Income Interest
InvestmentIncomeInterest
72000
CY2019Q2 us-gaap Interest Expense
InterestExpense
219000
CY2018Q2 us-gaap Interest Expense
InterestExpense
1447000
us-gaap Interest Expense
InterestExpense
445000
us-gaap Interest Expense
InterestExpense
2851000
CY2019Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-22000
CY2018Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1001000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
996000
CY2018Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-155000
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-317000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
341000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4092000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-9232000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-6674000
us-gaap Net Income Loss
NetIncomeLoss
-16525000
us-gaap Net Income Loss
NetIncomeLoss
-11077000
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.33
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-8.95
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.63
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-14.85
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27932610
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
745812
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26224986
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
745812
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
210000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
238000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-7293000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
44082000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
86000
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
46277000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
126000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
270000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-97416000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
104000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
16000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
62000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
17000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
-108360000
us-gaap Profit Loss
ProfitLoss
-16525000
us-gaap Profit Loss
ProfitLoss
-11077000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
74000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
54000
us-gaap Share Based Compensation
ShareBasedCompensation
166000
us-gaap Paid In Kind Interest
PaidInKindInterest
254000
us-gaap Paid In Kind Interest
PaidInKindInterest
2761000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6639000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
429000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
46308000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
3089000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
1995000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
948000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2019000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-115000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1243000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-115000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1463000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
149000
phas Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
11000
phas Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-5000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18865000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-429000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-28000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
126000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
938000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
48585000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1995000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
29291000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4672000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61051000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13406000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
90342000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8734000
us-gaap Interest Paid Net
InterestPaidNet
191000
us-gaap Interest Paid Net
InterestPaidNet
90000
phas Accrued Interest On Term Loan Refinanced To Principal
AccruedInterestOnTermLoanRefinancedToPrincipal
308000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
296000
phas Debt Refinanced With New Term Loan
DebtRefinancedWithNewTermLoan
6563000
phas Initial Recognition Of Operating Lease Right Of Use Assets And Operating Lease Liabilities
InitialRecognitionOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilities
1991000
phas Accretion Of Redeemable Convertible Preferred Stock
AccretionOfRedeemableConvertiblePreferredStock
33000
phas Deferred Stock Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredStockOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
31000
phas Deferred Stock Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredStockOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
604000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s condensed financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s condensed financial statements and accompanying notes. The most significant estimates in the Company&#8217;s condensed financial statements relate to the valuation of redeemable convertible preferred stock warrants prior to the IPO, the conversion option on the convertible notes prior to conversion and clinical trial accruals. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains certain deposit accounts and money market funds in federally insured financial institutions in excess of federally insured limits. The Company could experience losses on the money market funds in the future.</p>
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1785000
CY2019Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
302000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1358000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
166000
CY2019Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
671000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
914000
CY2019Q2 us-gaap Interest Payable Current
InterestPayableCurrent
54000
CY2018Q4 us-gaap Interest Payable Current
InterestPayableCurrent
194000
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
266000
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
141000
CY2019Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
459000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
305000
CY2019Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y6M
CY2019Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.064
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
The Company effected a 11.0634-for-1 reverse split of its outstanding common stock and redeemable convertible preferred stock.
CY2019Q2 phas Working Capital
WorkingCapital
89200000
CY2018Q4 us-gaap Restricted Cash
RestrictedCash
20000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2558448
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10827750
CY2019Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2536000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2140000
CY2019Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1859000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
163000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
372000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
377000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
363000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2323000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
272000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
776000
CY2019Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2018Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
200000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
200000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
270000
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
62000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
508000
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1864000

Files In Submission

Name View Source Status
0001564590-19-031993-index-headers.html Edgar Link pending
0001564590-19-031993-index.html Edgar Link pending
0001564590-19-031993.txt Edgar Link pending
0001564590-19-031993-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
phas-10q_20190630.htm Edgar Link pending
phas-20190630.xml Edgar Link completed
phas-20190630.xsd Edgar Link pending
phas-20190630_cal.xml Edgar Link unprocessable
phas-20190630_def.xml Edgar Link unprocessable
phas-20190630_lab.xml Edgar Link unprocessable
phas-20190630_pre.xml Edgar Link unprocessable
phas-ex311_8.htm Edgar Link pending
phas-ex312_9.htm Edgar Link pending
phas-ex321_7.htm Edgar Link pending
phas-ex322_6.htm Edgar Link pending
phas-ex46_30.htm Edgar Link pending
phas-ex47_29.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending